Innovative Diagnostic Portfolio Diazyme Laboratories offers a diverse range of proprietary enzyme-based diagnostic reagents for major health concerns such as cardiovascular, liver, gastro health, cancer, and renal diseases, positioning it as a comprehensive provider for laboratories seeking versatile testing solutions.

Recent Product Highlights The company has recently launched enhanced diagnostic assays, including colorimetric lithium tests and sample extraction demonstration videos, indicating ongoing innovation and support for laboratory workflow optimization, creating potential upsell opportunities.

Strategic Partnerships Collaborations with organizations like Ortho Clinical Diagnostics and partnerships with biotech companies such as Maccura Biotechnology showcase Diazyme’s access to extensive distribution channels and markets, providing avenues to expand sales through bundled offerings or joint marketing.

Regulatory Achievements With FDA EUA approvals for critical diagnostic tests like SARS-CoV-2 RT-PCR and FDA 510(k) exemptions, Diazyme demonstrates compliance and product reliability, making its solution attractive to labs prioritizing regulatory standards and enabling growth into new testing markets.

Growing Market Presence Operating in the biotechnology and diagnostics industry with revenues between $25 million and $50 million, alongside recent industry event participation, positions Diazyme to leverage emerging trends in automated testing and disease diagnostics for expanding customer base.